Standard Operating Procedure.docVIP

Standard Operating Procedure Example: Research using Streptozotocin (STZ) PI: Lab Location: Issue Date: ___ Revision Date: Prepared by: _ Approved by: ___________ Background: Streptozotocin (STZ) is used in animal research to induced diabetes. It is also used in the medical field as a chemotherapeutic drug. The compound is a light yellow, crystalline solid derived from Streptomyces achromogenes. It presents the highest exposure risk in the forms of powder and aerosols, as it is toxic and carcinogenic, but not volatile. It is most commonly prepared as a solution for injection, and is typically prepared immediately prior to a procedure. Hazard Identification: Chemical-Physical Properties Synonyms: STZ CAS#: 18883-66-4 Molecular formula: C8H15N3O7 Molecular weight: 265.22 g/mole Form: Light yellow, crystalline solid Solubility: Soluble in cold water, hot water. Soluble in lower alcohols, and ketones. Insoluble in non-polar organic solvents. Slightly soluble in polar organic solvents. Volatility: Not Applicable Structure of Streptozotocin (STZ) Toxic Properties Acute effects: Irritant to eyes, skin and respiratory tract. The lethal dose when delivered intravenously to mice was 275 mg/kg (LD50) and orally 3000 mg/kg (LD50). The toxic dose low (TDL) for humans is 1044 mg/kg/5days. Chronic effects: STZ is carcinogenic, mutagenic, and possibly teratogenic in humans. Prolonged or repeated exposure to STZ either through inhalation or ingestion can damage the blood and bone marrow. It can damage the kidneys and liver or cause cancer. It can affect the pancreas and cause diabetes. Local effects: Very hazardous in case of eye or skin contact, inhalation, or ingestion. Can cause gastrointestinal tract irritation with nausea and vomiting. If inhaled, symptoms similar t